Comparative Pharmacology
Head-to-head clinical analysis: BRAVELLE versus GONAL F RFF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRAVELLE versus GONAL F RFF.
BRAVELLE vs GONAL-F RFF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing cAMP production and promoting follicular development.
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular growth and maturation and spermatogenesis.
For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.
Subcutaneous injection, initially 75-150 IU once daily for 5-7 days for ovulation induction. For controlled ovarian hyperstimulation, 75-300 IU once daily starting day 2 or 3 of cycle. Dose adjusted based on response.
None Documented
None Documented
Terminal elimination half-life approximately 5-6 hours in healthy adults. Extended in renal impairment (up to 24 hours with CrCl <30 mL/min).
Terminal elimination half-life: approximately 24-30 hours (range 24-36 h) following subcutaneous administration; supports once-daily dosing regimen.
Primarily renal: 95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal: 5% eliminated via feces.
Renal excretion: approximately 70% of the dose is eliminated in urine as intact hormone and metabolites; fecal excretion is negligible (<5%).
Category C
Category C
Gonadotropin
Gonadotropin